ASCO GU Conference Coverage
(Curetoday.com) Feb 15, 2019 - The Food and Drug Administration (FDA) granted a priority review to Keytruda (pembrolizumab) in combination with Inlyta (axitinib) as a frontline treatment for advanced renal cell carcinoma (RCC), according to Merck, the manufacturer of the anti-PD-1 therapy.
“Many patients with advanced renal cell...
(Pharmaphorum.com [UK]) Feb 15, 2019 - Bayer and development partner Orion have released detailed results from the trial that will form the backbone of its filing for their latest prostate cancer drug, as they aim to take on two established blockbusters from Johnson & Johnson and Pfizer/Astellas.
J&J and Astellas market androgen...
There are no ASCO GU Conference Coverage OBR Green articles.